BUSINESS

Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit

By Kohei Hori January 30, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Takeda Pharmaceutical will revamp its organizational structure effective April 1 as the company prepares for the leadership transition — the first in 12 years — to CEO-elect Julie Kim in June 2026. The biggest change is the creation of a…

To read the full story

Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
June 26, 2025
Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025

BUSINESS

Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
Japan Ethical Drug Sales Up 1.2% in January: Crecon
March 9, 2026
Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…